


Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A conjugate of polyethylene glycol hydrophilic polymers and the molecules from boxwood extraction or the synthetic derivatives of the molecules, represented by formula I:



(I)

wherein:

P is a hydrophilic polymer, which is selected from a group consisting of polyethylene glycol, polyglutamic acid, polyaspartic acid, polypropylene, polyvinyl alcohol, polyacrylmorpholine and their copolymer thereof;

n is an integer, not exceed the total number of hydroxy and amine group on the D;


L is a linking group, which is selected from a group consisting of: ester, carbonate, urethane, ether, acetal, and amide;

D is a molecule from the extraction of boxwood or its synthetic derivative, selected from a group consisting of Cyclovirobuxine D, Cycloprotobuxine A, Cycloprotobuxine C, Cyclovirobuxine C and their derivatives.

2. (currently amended) The conjugate of claim 1 wherein free hydroxyl on said hydrophilic polymer polyethylene glycol can be substituted by C₁₋₁₂ alkoxy, cycloalkoxy or aroxy.

3. (currently amended) The conjugate of claim 1, wherein said ~~the hydrophilic polymer is~~ polyethylene glycol, which has an average molecular weight from 300 to 60000.

4. (original) A conjugate of claim 1, wherein said molecule from boxwood extraction is Cyclovirobuxine D, and the conjugate is represented by formula (I-D₁):



wherein:

P' is independently selected from H or P, but not all be H at the same time;

L is a linker group as disclosed previously.

5. (currently amended) The conjugate of claim 1, wherein said, the linkage between the ~~hydrophilic polymer polyethylene glycol~~ and the molecule is an ester linker.

6. (currently amended) The conjugate of claim 1, wherein said, the conjugate is selected from a group consisting of N,N'-di(α -methoxy- ω -carboxyl-polyethylene glycol)-Cyclovirobuxine D (1), α -methoxy-polyethylene-glycol-acetic-acid-Cyclovirobuxine D ester

(4), and α -methoxy- ω -carboxyl-polyethylene glycol-glycine-Cyclovirobuxine D ester (7).

7. (canceled)

8. (canceled)

9. (canceled)

10. (currently amended) A composition comprising any conjugate of claim 1-69 and pharmaceutically acceptable carrier and excipient.

11. (original) The composition of claim 10, wherein said composition may be formulated into therapeutic acceptable formular, including tablet, suppository, pill, soft and hard gelatin capsules, powder, solution, suspension and aerosol.